Mifepristone: The debate continues
Much debate continues over the appropriateness of the Food and Drug Administration’s (FDA) decision to approve mifepristone (Mifeprex), formerly known as RU486, for medical abortions.
When mifepristone was first approved, the American Medical Women’s Association (AMWA) commended the FDA for making another option available to women. AMWA stated that it believed mifepristone would go a long way to improve options for women in early pregnancy. The organization has since published a supplement to its Journal of the American Medical Women’s Association featuring articles educating readers about mifepristone. A copy of the supplement can be obtained by calling Melisa Marin at (703) 838-0500.
In the other camp sits Rock for Life. This group declares that the FDA’s decision has "escalated chemical warfare." (See www.rockforlife.org.)
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content